Copy to clipboard 
Stryker reported 4Q25 orthopedic sales of $3.1 billion, up 2.5% compared to the fourth quarter of 2024. For the full year, the company generated $11.2 billion in orthopedic sales, up 4.7% compared to the prior year. Excluding revenues from Stryker’s divested spinal implant business, the company grew 9% for the quarter and 10.1% for the year.
The company set another record quarter for Mako installs, and now has a worldwide install base over 3,000 systems. Utilization numbers are impressive, as well. Two-thirds of Stryker’s U.S. knee implants are performed using Mako, while one-third of its U.S. hips use the robot.
Mako 4 is the first time the actual system has changed since Stryker bought Mako, and management wasn’t sure how the transition would go. However, early feedback has been very positive, while the installation numbers speak for themselves.
“Mako 4 has been an absolute home run,” said Stryker CEO Kevin Lobo. “We already felt like we had the best robot in the market, and we’ve just only added to that with these additional applications. The feedback on revision hip, one surgeon actually told me he thought it was a cheat code for revisions. Those were his words. It just makes a very hard procedure very easy to do, providing tremendous value to the surgeon.”
Hip implant sales were further driven by the success of the Insignia Hip Stem, while shoulders continue to experience double-digit growth, and Mako Shoulder gets closer to launch.
Core trauma faced steep comparators from last year, slower foot and ankle sales and approval delays in Europe because of EU MDR. Sports medicine sales were driven by shoulder repair products and the 1788 camera system.
Stryker expects organic growth between 8% and 9.5% in 2026.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $1,522.0 | $1,397.7 | $124.3 | 8.9% |
| Knees | $749.2 | $687.6 | $61.6 | 9% |
| Hips | $498.5 | $461.1 | $37.4 | 8.1% |
| Extremities | $274.3 | $249.0 | $25.3 | 10.2% |
| Spine | $8.0 | $186.0 | ($178.0) | (95.7%) |
| Trauma | $812.1 | $746.9 | $65.1 | 8.7% |
| Sports Medicine | $255.1 | $227.8 | $27.3 | 12% |
| Orthobiologics | $87.3 | $86.0 | $1.3 | 1.5% |
| Enabling Technology | $175.2 | $144.6 | $30.6 | 21.2% |
| Other | $255.5 | $248.8 | $6.7 | 2.7% |
| Total | $3,115.2 | $3,037.9 | $77.3 | 2.5% |
| Segment | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $5,511.3 | $5,031.3 | $479.9 | 9.5% |
| Knees | $2,656.0 | $2,447.5 | $208.5 | 8.5% |
| Hips | $1,865.7 | $1,703.1 | $162.6 | 9.5% |
| Extremities | $989.5 | $880.7 | $108.8 | 12.4% |
| Spine | $184.6 | $706.9 | ($522.3) | (73.9%) |
| Trauma | $2,957.8 | $2,625.9 | $331.9 | 12.6% |
| Sports Medicine | $875.2 | $789.7 | $85.6 | 10.8% |
| Orthobiologics | $320.9 | $316.8 | $4.1 | 1.3% |
| Enabling Technology | $534.5 | $453.9 | $80.6 | 17.8% |
| Other | $836.2 | $789.0 | $47.2 | 6% |
| Total | $11,220.5 | $10,713.5 | $506.9 | 4.7% |
Orthopedic Sales by Geography
| Region | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $2,218.0 | $2,180.3 | $37.7 | 1.7% |
| OUS | $897.2 | $857.5 | $39.6 | 4.6% |
| EMEA | $400.3 | $394.9 | $5.4 | 1.4% |
| Asia Pacific | $358.2 | $334.2 | $24.1 | 7.2% |
| Rest of World | $138.6 | $128.4 | $10.2 | 7.9% |
| Total | $3,115.2 | $3,037.9 | $77.3 | 2.5% |
| Region | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $7,951.1 | $7,609.0 | $342.1 | 4.5% |
| OUS | $3,269.4 | $3,104.5 | $164.8 | 5.3% |
| EMEA | $1,494.5 | $1,450.7 | $43.8 | 3% |
| Asia Pacific | $1,148.7 | $1,085.0 | $63.7 | 5.9% |
| Rest of World | $626.2 | $568.9 | $57.3 | 10.1% |
| Total | $11,220.5 | $10,713.5 | $506.9 | 4.7% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $7,171.0 | |
| Cost of Sales | $2,543.0 | 35.5% |
| Selling and Admin | $2,227.0 | 31.1% |
| R & D | $401.0 | 5.6% |
| Other | $1,151.0 | 16.1% |
| Net Earnings | $849.0 | 11.8% |
Stryker reported 4Q25 orthopedic sales of $3.1 billion, up 2.5% compared to the fourth quarter of 2024. For the full year, the company generated $11.2 billion in orthopedic sales, up 4.7% compared to the prior year. Excluding revenues from Stryker's divested spinal implant business, the company grew 9% for the quarter and 10.1% for the...
Stryker reported 4Q25 orthopedic sales of $3.1 billion, up 2.5% compared to the fourth quarter of 2024. For the full year, the company generated $11.2 billion in orthopedic sales, up 4.7% compared to the prior year. Excluding revenues from Stryker’s divested spinal implant business, the company grew 9% for the quarter and 10.1% for the year.
The company set another record quarter for Mako installs, and now has a worldwide install base over 3,000 systems. Utilization numbers are impressive, as well. Two-thirds of Stryker’s U.S. knee implants are performed using Mako, while one-third of its U.S. hips use the robot.
Mako 4 is the first time the actual system has changed since Stryker bought Mako, and management wasn’t sure how the transition would go. However, early feedback has been very positive, while the installation numbers speak for themselves.
“Mako 4 has been an absolute home run,” said Stryker CEO Kevin Lobo. “We already felt like we had the best robot in the market, and we’ve just only added to that with these additional applications. The feedback on revision hip, one surgeon actually told me he thought it was a cheat code for revisions. Those were his words. It just makes a very hard procedure very easy to do, providing tremendous value to the surgeon.”
Hip implant sales were further driven by the success of the Insignia Hip Stem, while shoulders continue to experience double-digit growth, and Mako Shoulder gets closer to launch.
Core trauma faced steep comparators from last year, slower foot and ankle sales and approval delays in Europe because of EU MDR. Sports medicine sales were driven by shoulder repair products and the 1788 camera system.
Stryker expects organic growth between 8% and 9.5% in 2026.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $1,522.0 | $1,397.7 | $124.3 | 8.9% |
| Knees | $749.2 | $687.6 | $61.6 | 9% |
| Hips | $498.5 | $461.1 | $37.4 | 8.1% |
| Extremities | $274.3 | $249.0 | $25.3 | 10.2% |
| Spine | $8.0 | $186.0 | ($178.0) | (95.7%) |
| Trauma | $812.1 | $746.9 | $65.1 | 8.7% |
| Sports Medicine | $255.1 | $227.8 | $27.3 | 12% |
| Orthobiologics | $87.3 | $86.0 | $1.3 | 1.5% |
| Enabling Technology | $175.2 | $144.6 | $30.6 | 21.2% |
| Other | $255.5 | $248.8 | $6.7 | 2.7% |
| Total | $3,115.2 | $3,037.9 | $77.3 | 2.5% |
| Segment | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $5,511.3 | $5,031.3 | $479.9 | 9.5% |
| Knees | $2,656.0 | $2,447.5 | $208.5 | 8.5% |
| Hips | $1,865.7 | $1,703.1 | $162.6 | 9.5% |
| Extremities | $989.5 | $880.7 | $108.8 | 12.4% |
| Spine | $184.6 | $706.9 | ($522.3) | (73.9%) |
| Trauma | $2,957.8 | $2,625.9 | $331.9 | 12.6% |
| Sports Medicine | $875.2 | $789.7 | $85.6 | 10.8% |
| Orthobiologics | $320.9 | $316.8 | $4.1 | 1.3% |
| Enabling Technology | $534.5 | $453.9 | $80.6 | 17.8% |
| Other | $836.2 | $789.0 | $47.2 | 6% |
| Total | $11,220.5 | $10,713.5 | $506.9 | 4.7% |
Orthopedic Sales by Geography
| Region | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $2,218.0 | $2,180.3 | $37.7 | 1.7% |
| OUS | $897.2 | $857.5 | $39.6 | 4.6% |
| EMEA | $400.3 | $394.9 | $5.4 | 1.4% |
| Asia Pacific | $358.2 | $334.2 | $24.1 | 7.2% |
| Rest of World | $138.6 | $128.4 | $10.2 | 7.9% |
| Total | $3,115.2 | $3,037.9 | $77.3 | 2.5% |
| Region | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $7,951.1 | $7,609.0 | $342.1 | 4.5% |
| OUS | $3,269.4 | $3,104.5 | $164.8 | 5.3% |
| EMEA | $1,494.5 | $1,450.7 | $43.8 | 3% |
| Asia Pacific | $1,148.7 | $1,085.0 | $63.7 | 5.9% |
| Rest of World | $626.2 | $568.9 | $57.3 | 10.1% |
| Total | $11,220.5 | $10,713.5 | $506.9 | 4.7% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $7,171.0 | |
| Cost of Sales | $2,543.0 | 35.5% |
| Selling and Admin | $2,227.0 | 31.1% |
| R & D | $401.0 | 5.6% |
| Other | $1,151.0 | 16.1% |
| Net Earnings | $849.0 | 11.8% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
